MRNA vaccine takes on Hard-to-Treat cancers in early trial

NCT ID NCT07100210

Recruiting now Disease control Sponsor: Xingchen Peng Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early study tests a new mRNA vaccine (IL-22BP) for people with advanced solid tumors like sarcoma, head and neck cancer, or melanoma that have not responded to standard treatments. The vaccine is injected directly into tumors. Only 6 participants are enrolled to check safety and see if tumors shrink. It is too early to know if it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IL-22BP mRNA vaccine
What this could lead to: If it works, this could point toward a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong: This is a very early, small Phase 1 trial with only 6 participants, so it is too soon to know if the vaccine is effective. The main goal is safety, and there may be side effects or no benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck squamous cell carcinoma melanoma refractory malignant neoplasm soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INTERLEUKIN MRNA VACCINE REFRACTORY MALIGNANT SOLID TUMORS

Contacts and locations

Locations

West China Hospital of Sichuan University
RECRUITING

Chengdu, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.